Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer.
E. A. Wellberg, K. A. Corleto, L. A. Checkley, S. Jindal, G. Johnson, J. A. Higgins, S. Obeid, S. M. Anderson, A. D. Thor, P. J. Schedin, P. S. MacLean, E. D. Giles
Abstract
Obesity and adult weight gain are linked to increased breast cancer risk and poorer clinical outcomes in postmenopausal women, particularly for hormone-dependent tumors. Menopause is a time when significant weight gain occurs in many women, and clinical and preclinical studies have identified menopause (or ovariectomy) as a period of vulnerability for breast cancer development and promotion. We hypothesized that preventing weight gain after ovariectomy (OVX) may be sufficient to prevent the formation of new tumors and decrease growth of existing mammary tumors. Here, we tested this hypothesis in a rat model of obesity and carcinogen-induced postmenopausal mammary cancer and validated our findings in a murine xenograft model with implanted human tumors. In both models, preventing weight gain after OVX significantly decreased obesity-associated tumor development and growth. Importantly, we did not induce weight loss in these animals, but simply prevented weight gain. In both lean and obese rats, preventing weight gain reduced visceral fat accumulation and associated insulin resistance. Similarly, the intervention decreased circulating tumor-promoting growth factors and inflammatory cytokines (ie, BNDF, TNF, FGF2), with greater effects in obese compared to lean rats. In obese rats, preventing weight gain decreased adipocyte size, adipose tissue macrophage infiltration, reduced expression of the tumor-promoting growth factor FGF-1, and reduced phosphorylated FGFR in tumors. Together, these findings suggest that the underlying mechanisms associated with the anti-tumor effects of weight maintenance are multifactorial, and that weight maintenance during the peri-/post-menopausal period may be a viable strategy for reducing obesity-associated breast cancer risk and progression in women.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeting the menopause transition with metformin improves breast cancer outcomes, but discontinuation has deleterious effects on metabolic health: Findings from a preclinical model of postmenopausal breast cancer.
Karen A. Corleto, Pepper S. Schedin, … Erin Danielle Giles·bioRxiv·Nov 25, 2024
- Trem2 deficiency attenuates breast cancer tumor growth in lean, but not obese or weight loss, mice and is associated with alterations of clonal T cell populations
Elysa W. Pierro, Matthew A. Cottam, … Alyssa H. Hasty·Cancer ResearchPeer-reviewed·Jan 22, 2025
- Breast cancer endocrine therapy exhausts adipocyte progenitors promoting weight gain and glucose intolerance
R. L. Scalzo, R. M. Foright, … E. A. Wellberg·bioRxiv·Aug 21, 2020
- Lean breast adipocytes secrete an oxylipin that suppresses breast cancer via ferroptosis
Meghan C. Curtin, Abigail E. Jackson, … Keren I. Hilgendorf·SciencePeer-reviewed·Sep 10, 2026
- Alterations in the Mammary Gland and Tumor Microenvironment of Formerly Obese Mice
G. Kuziel, B. N. Moore, … L. M. Arendt·bioRxiv·Jun 14, 2023
- Response to immune checkpoint blockade improved in pre-clinical model of breast cancer after bariatric surgery
L. M. Sipe, M. Chaib, … L. Makowski·bioRxiv·Mar 30, 2022